DSFIRN Stock Chart & Stats
$1301.79
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$1,301.79 - $2,528.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$387.73B
Enterprise ValueN/A
Total Cash (Recent Filing)$1.90B
Total Debt (Recent Filing)$5.28B
Price to Earnings (P/E)―
Beta0.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding253,626,950
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.98
Price to Sales (P/S)1.97
P/FCF Ratio28.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthDSM‑Firmenich maintains a relatively solid balance sheet with moderate leverage and a meaningful equity base. That structural cushion supports capital allocation, resilience to market shocks, and the ability to invest in R&D or M&A over the next several quarters, even as profits wobble.
Positive Cash GenerationThe company continues to generate positive operating and free cash flow, underpinning ongoing operations and shareholder returns. Persistent cash generation even in weaker earnings years provides a durable ability to fund working capital, capex and maintain strategic investments over a 2–6 month horizon.
Diversified B2B Franchise & Customer Lock‑inDSM‑Firmenich’s diversified portfolio—perfume/beauty, flavors/texture, and nutrition—plus application labs and co‑creation creates strong customer stickiness. Multi‑year contracts and formulation services embed products in customers’ supply chains, supporting recurring revenue and pricing leverage over time.
Bears Say
Volatile Revenue And Net LossRevenue volatility and the swing to a sizable net loss in 2025 point to unstable demand, margin mix issues, or episodic charges. This undermines predictable earnings and complicates planning, reducing visibility for reinvestment and raising the risk that earnings may remain uneven over the medium term.
Weakened Cash ConversionAlthough cash flows remain positive, cash conversion has deteriorated and free cash flow declined in 2025. Choppy conversion reduces the reliability of cash for discretionary uses, heightens sensitivity to further margin shocks, and constrains the firm’s ability to consistently fund strategic growth or absorb losses.
Eroding Equity CushionReported equity stepped down into 2025 alongside weaker results, which reduces the balance‑sheet buffer against shocks. A thinner equity base limits financial flexibility for large investments or acquisitions and raises the relative impact of future losses on leverage ratios over coming quarters.
DSFIRN FAQ
What was DSM-Firmenich AG’s price range in the past 12 months?
DSM-Firmenich AG lowest stock price was $1301.79 and its highest was $2528.25 in the past 12 months.
What is DSM-Firmenich AG’s market cap?
DSM-Firmenich AG’s market cap is $387.73B.
When is DSM-Firmenich AG’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were DSM-Firmenich AG’s earnings last quarter?
Currently, no data Available
Is DSM-Firmenich AG overvalued?
According to Wall Street analysts DSM-Firmenich AG’s price is currently Undervalued.
Does DSM-Firmenich AG pay dividends?
DSM-Firmenich AG does not currently pay dividends.
What is DSM-Firmenich AG’s EPS estimate?
DSM-Firmenich AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DSM-Firmenich AG have?
DSM-Firmenich AG has 253,626,950 shares outstanding.
What happened to DSM-Firmenich AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DSM-Firmenich AG?
Currently, no hedge funds are holding shares in MX:DSFIRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.